Taiwan Advanced Nanotech Inc.
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan. The company provides automated extraction instruments; nucleic acid extraction kit that extracts DNA/RNA from samples of blood, cell, tissue, plant, bacteria, virus, etc.; consumables, such as spin tips and deep well plat… Read more
Taiwan Advanced Nanotech Inc. (6797) - Total Liabilities
Latest total liabilities as of June 2025: NT$450.26 Million TWD
Based on the latest financial reports, Taiwan Advanced Nanotech Inc. (6797) has total liabilities worth NT$450.26 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Taiwan Advanced Nanotech Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Taiwan Advanced Nanotech Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Taiwan Advanced Nanotech Inc. Competitors by Total Liabilities
The table below lists competitors of Taiwan Advanced Nanotech Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daewon Co. Ltd
KQ:007680
|
Korea | ₩219.50 Billion |
|
artnet AG
PINK:ARTZF
|
USA | $10.17 Million |
|
JCBNext Berhad Bhd
KLSE:0058
|
Malaysia | RM7.57 Million |
|
Chromocell Therapeutics Corporation
NYSE MKT:CHRO
|
USA | $7.32 Million |
|
Cosmos Health Inc.
NASDAQ:COSM
|
USA | $46.36 Million |
|
FORIS AG
F:FRS
|
Germany | €3.31 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Taiwan Advanced Nanotech Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Taiwan Advanced Nanotech Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Taiwan Advanced Nanotech Inc. (2019–2024)
The table below shows the annual total liabilities of Taiwan Advanced Nanotech Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$368.69 Million | -38.30% |
| 2023-12-31 | NT$597.53 Million | -27.01% |
| 2022-12-31 | NT$818.64 Million | -11.37% |
| 2021-12-31 | NT$923.67 Million | -1.22% |
| 2020-12-31 | NT$935.03 Million | +969.25% |
| 2019-12-31 | NT$87.45 Million | -- |